KRAS and non-small cell lung carcinoma: MRTX849 (adagrasib) is another KRAS inhibitor that successfully targets the KRAS G12C protein.92 This drug, with a slightly different chemical structure, also irreversibly and selectively binds and locks KRAS G12C in its inactive GDP-bound state, with a longer half-life than AMG510.93 MRTX849 is the second (and last) KRAS G12C direct inhibitor to be approved and is indicated as a 2nd-line treatment for metastatic NSCLC with the KRAS G12C mutation.94 This approval was based on the Krystal-1 (NCT03785249) trial, which we discuss in detail later in this review.